NEUROGEN PHARMA Focused on Neurology, Pain Management & Allergy Files HKEX Listing Application
NewTimeSpace News: NeuroGen Pharma Limited submitted its Main Board listing application to the Hong Kong Stock Exchange on 25 June, with JPMorgan, CICC and HSBC acting as joint sponsors. The Company is a clinical-value-driven specialty pharmaceutical platform focusing on neurology, pain management and allergy therapeutics in China. Following its acquisition of UCB’s relevant China business and assets, it has built an integrated platform anchored by well-established originator brands including Keppra®, Vimpat®, Zyrtec® and recently approved Xyzal®.
NewTimeSpace News: NeuroGen Pharma Limited filed a Main Board listing application with the Hong Kong Stock Exchange on 25 June 2026, jointly sponsored by JPMorgan, CICC and HSBC.
The Company is a clinical-value-oriented specialty pharmaceutical platform with solid revenue base and robust growth potential, concentrating on three core therapeutic areas in China: neurology, pain management and allergic disorders. It adopts a differentiated operational model integrating marketed originator medicines, innovative clinical-stage pipeline assets, selective business development opportunities, and end-to-end capabilities covering R&D, manufacturing and commercialization.
Upon completing the acquisition of UCB’s neurology and allergy business as well as related assets in China, the Group has established a fully integrated platform covering these therapeutic segments. Its core asset portfolio comprises renowned originator brands including Keppra® (levetiracetam), Vimpat® (lacosamide), Zyrtec® (cetirizine dihydrochloride) and the newly approved Xyzal® (levocetirizine dihydrochloride), backed by a growing pipeline of candidates targeting neurology, pain management and allergy indications.
The therapeutic fields the Group serves feature unmet clinical demand, high professional and operational entry barriers, and clear product differentiation characteristics.
Tags：
- China Merchants CSI Animal Husbandry ETF(516670) rises 2.05% against the market trend, with a share increase of 1.093 billion units over the past 3 months
- Tracker Fund Of Hong Kong(02800.HK) Down 2.30% in Early Trading, Turnover Reaches HK$5.337 Billion
- Ping An of China CSI HK Dividend ETF(03070.HK) Slips 1.65% in Early Trading, Asset Size Hits HK$1.357 Billion
- Hang Seng S&P 500 Index ETF (Listed Class)(03195.HK) Drops 1.62% in Early Trading, Average Price at HK$11.609
- GREAT HARVEST(03683.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of USD 6.05 million, loss narrowed by 41.72% YoY
